• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I型成骨不全症中的高钙尿症

Hypercalciuria in osteogenesis imperfecta type I.

作者信息

Ammenti A, Nitsch M

机构信息

Department of Pediatrics, University of Parma School of Medicine, Parma, Italy.

出版信息

Klin Padiatr. 2003 Sep-Oct;215(5):283-5. doi: 10.1055/s-2003-42665.

DOI:10.1055/s-2003-42665
PMID:14520592
Abstract

BACKGROUND

In Osteogenesis Imperfecta severity of disease and reduced physical activity have been considered the main factors contributing to hypercalciuria; however, its pathogenesis in Osteogenesis Imperfecta Type I, in which mobility is normal, is still unclear.

PATIENT, METHODS AND RESULTS: We describe a patient with Osteogenesis Imperfecta Type I and hypercalciuria, in whom measurement of calcium intake, plasma 1 - 25(OH) (2) Vitamin D, fasting calciuria and tubular proteinuria led us to exclude an absorptive or renal component in the pathogenesis of hypercalciuria.

CONCLUSIONS

We believe that hypercalciuria is determined by bone disease in Osteogenesis Imperfecta Type I. This condition should be added to the causes of normocalcemic hypercalciuria in children and the mildest forms should be differentiated from Idiopathic Hypercalciuria.

摘要

背景

在成骨不全症中,疾病严重程度和体力活动减少被认为是导致高钙尿症的主要因素;然而,在I型成骨不全症中,其发病机制尚不清楚,该型患者活动能力正常。

患者、方法与结果:我们描述了一名患有I型成骨不全症和高钙尿症的患者,通过测量钙摄入量、血浆1,25(OH)₂维生素D、空腹尿钙和肾小管蛋白尿,我们排除了高钙尿症发病机制中的吸收性或肾脏因素。

结论

我们认为,I型成骨不全症中的高钙尿症是由骨病决定的。这种情况应被列入儿童正常血钙性高钙尿症的病因中,最轻微的形式应与特发性高钙尿症相鉴别。

相似文献

1
Hypercalciuria in osteogenesis imperfecta type I.I型成骨不全症中的高钙尿症
Klin Padiatr. 2003 Sep-Oct;215(5):283-5. doi: 10.1055/s-2003-42665.
2
Hypercalciuria in children severely affected with osteogenesis imperfecta.患有严重成骨不全症儿童的高钙尿症。
J Pediatr. 1991 Jul;119(1 Pt 1):51-7. doi: 10.1016/s0022-3476(05)81038-8.
3
Subdural hematoma as clinical presentation of osteogenesis imperfecta.硬膜下血肿作为成骨不全的临床表现。
Pediatr Neurol. 2005 Feb;32(2):140-2. doi: 10.1016/j.pediatrneurol.2004.07.011.
4
Urinary-free amino acids in osteogenesis imperfecta.成骨不全症患者尿中的游离氨基酸
Bone. 1986;7(1):13-5. doi: 10.1016/8756-3282(86)90146-8.
5
Hypercalciuria in osteogenesis imperfecta.成骨不全症中的高钙尿症。
J Pediatr. 1992 Feb;120(2 Pt 1):330-1. doi: 10.1016/s0022-3476(05)80457-3.
6
Vitamin D metabolism in osteogenesis imperfecta during calcitonin therapy.
Pediatrics. 1984 Apr;73(4):538-42.
7
Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.成骨不全症患儿和青少年的生化骨标志物评估及帕米膦酸盐治疗。
Acta Paediatr. 2010 Dec;99(12):1834-40. doi: 10.1111/j.1651-2227.2010.01968.x. Epub 2010 Aug 19.
8
Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.静脉注射帕米膦酸治疗36个月以下成骨不全患儿。
Bone. 2004 Nov;35(5):1038-45. doi: 10.1016/j.bone.2004.07.003.
9
[Osteogenesis imperfecta].[成骨不全症]
Presse Med. 2007 Dec;36(12 Pt 2):1787-93. doi: 10.1016/j.lpm.2007.01.043. Epub 2007 Jun 8.
10
Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.儿童及青少年 VI 型成骨不全症:静脉注射帕米膦酸二钠周期性治疗的效果
Bone. 2007 Mar;40(3):638-44. doi: 10.1016/j.bone.2006.10.010. Epub 2006 Nov 28.